NRC — National Research Balance Sheet
0.000.00%
- $360.61m
- $435.51m
- $137.39m
- 95
- 45
- 65
- 78
Annual balance sheet for National Research, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 8-K |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 54.4 | 25 | 6.65 | 4.23 | 4.14 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 14.6 | 15.3 | 12.6 | 11.4 | 11.1 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 73.7 | 43.7 | 24.4 | 19.6 | 20.2 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 13.4 | 17.8 | 30.3 | 39.9 | 40.5 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 158 | 130 | 122 | 133 | 135 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 40.4 | 33.4 | 36.2 | 35.9 | 36.6 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 72.2 | 58.4 | 73.5 | 101 | 121 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 85.3 | 72 | 49 | 31.3 | 14 |
| Total Liabilities & Shareholders' Equity | 158 | 130 | 122 | 133 | 135 |
| Total Common Shares Outstanding |